A study co-author told Newsweek the test is already helping some National Health Service sites clear cystoscopy backlogs.

Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

A simple urine test can more than halve the number of cystoscopies necessary to follow up high-risk bladder cancer patients, new research has found. Cystoscopies involve inserting a flexible probe ...

Cystoscopy without the aid of urinary markers is the most cost-effective strategy for detecting recurrence of non-invasive bladder cancer, according to researchers. In a study that examined five ...

Designed to simplify setup, improve visualization, and expand maneuverability in cystoscopy procedures. BOTHELL, WA, UNITED STATES, May 15, 2026 /EINPresswire.com ...

At-home urine test can detect nine in 10 cases of bladder cancer - Around 10,900 new bladder cancer cases are diagnosed every ...

OSLO, Norway, June 23, 2021 /PRNewswire/ -- Photocure, The Bladder Cancer Company, announces the publication of a study in the journal Urologic Oncology. The study objective was to determine the ...

COLUMBIA, Md.--(BUSINESS WIRE)--Ambu Inc., the world leader in single-use endoscopes, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Organization for ...

Two new studies presented at the American Urological Association 2017 annual meeting clearly show that blue light cystoscopy offers a significant advantage over white light cystoscopy identifying ...

NEW ORLEANS -- Using a tool to classify patients' infection risk and providing education and systems-level changes in the urology department safely reduced prophylactic antibiotic use around ...

Rocky River, Ohio-based UroGPO entered into a contract with Ambu for a single-use endoscope. UroGPO has a three-year agreement in line for the Ambu aScope 4 Cysto and aView 2 Advance HD Monitor, ...